My watch list  


Systematic (IUPAC) name
3-[(2-chlorophenyl)methyl] -7-thia-3-azabicyclo[4.3.0] nona-8,10-diene
CAS number 55142-85-3
ATC code B01AC05
PubChem 5472
DrugBank APRD01257
Chemical data
Formula C14H14ClNS 
Mol. mass 263.786 g/mol
Pharmacokinetic data
Bioavailability >80%
Protein binding 98%
Metabolism Hepatic
Half life
  • 12 hours (single dose)
  • 4 to 5 days (after repeated dosing)
Excretion Renal and fecal
Therapeutic considerations
Pregnancy cat.

B1(AU) C(US)

Legal status
Routes Oral

Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. The usual dose is 250mg twice daily by the oral route.


  • Inihibits platelet aggregation by altering the function of platelet membranes.
  • Prolongs bleeding time.
  • Decreased incidence of stroke in high-risk patients.


  • Hypersensitivity
  • Bleeding disorders
  • Active bleeding
  • Severe liver disease


  • Risk of bleeding (trauma, surgery, history of peptic ulcer disease)
  • Renal or hepatic impairment
  • Geriatric patients (increased sensitivity)
  • Pregnancy, lactation, or children under 18
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ticlopidine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE